All rights reserved. This publication is intended for use solely by faculty, students, and staff of Nova Southeastern University. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, now known or later developed, including but not limited to photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author or the publisher.
Dissertation - NSU Access Only
Claire Ann Thuning
The availability of attenuated, bitypic, genetic recombinant strains of herpes simplex virus (HSV) made possible the following investigations.
The recombinant virus, D5E1, exhibited limited, short-lived replication in the central nervous system of mice and guinea pigs. Nevertheless, this virus was sufficient to stimulate substantial levels of neutralizing antibody and localized cellular immunity in genital tissue.
Immunization with D5El protected mice and/or guinea pigs against (HSV) type l and 2 infections when the challenge virus was given by a variety of pathways. In particular, it reduced vaginal virus shedding, inflammation, and acute and latent infection of the regional ganglia. The degree of protection in mice was influenced by the strain of rodent, the route of challenge and type of wild virus.
Vaccination of newborn mice with live, attenuated virus also resulted in protection against HSV-2 subsequently inoculated into the footpad.
The ability of recombinant HSV strains to establish latent ganglionic infection was related to their virulence, the route of inoculation and the genetic strain of the mouse.
The D5E1 vaccine failed to establish latent disease by itself, but nevertheless conferred good protection against HSV type 1 or 2 challenge of immunized mice or guinea pigs.
Nawal Ahmad Bakir. 1984. The Efficacy of an Intertypic Recombinant of Herpes Simplex Virus Type 1 and Type 2 Vaccine Against Experimental Herpetic Infection. Doctoral dissertation. Nova Southeastern University. Retrieved from NSUWorks, . (87)